Angiogenesis as a therapeutic target - PubMed

Affiliations

• PMID: 16355214
• DOI: 10.1038/nature04483

Review

Angiogenesis as a therapeutic target

Napoleone Ferrara et al. Nature. 2005.

Abstract

Inhibiting angiogenesis is a promising strategy for treatment of cancer and several other disorders, including age-related macular degeneration. Major progress towards a treatment has been achieved over the past few years, and the first antiangiogenic agents have been recently approved for use in several countries. Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first.

Similar articles

• Angiogenesis in life, disease and medicine.

  Carmeliet P. Carmeliet P. Nature. 2005 Dec 15;438(7070):932-6. doi: 10.1038/nature04478. Nature. 2005. PMID: 16355210 Review.

• Vascular remodeling and clinical resistance to antiangiogenic cancer therapy.

  Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Glade Bender J, et al. Drug Resist Updat. 2004 Aug-Oct;7(4-5):289-300. doi: 10.1016/j.drup.2004.09.001. Drug Resist Updat. 2004. PMID: 15533766 Review.

• Molecular mechanisms and therapeutic development of angiogenesis inhibitors.

  Cao Y. Cao Y. Adv Cancer Res. 2008;100:113-31. doi: 10.1016/S0065-230X(08)00004-3. Adv Cancer Res. 2008. PMID: 18620094 Review.

• Antiangiogenic therapy: a universal chemosensitization strategy for cancer?

  Kerbel RS. Kerbel RS. Science. 2006 May 26;312(5777):1171-5. doi: 10.1126/science.1125950. Science. 2006. PMID: 16728631

Cited by

• Properties of protein drug target classes.

  Bull SC, Doig AJ. Bull SC, et al. PLoS One. 2015 Mar 30;10(3):e0117955. doi: 10.1371/journal.pone.0117955. eCollection 2015. PLoS One. 2015. PMID: 25822509 Free PMC article.

• The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression.

  Doçi CL, Zhou G, Lingen MW. Doçi CL, et al. Oncogene. 2013 Sep 12;32(37):4377-86. doi: 10.1038/onc.2012.464. Epub 2012 Oct 22. Oncogene. 2013. PMID: 23085760 Free PMC article.

• Preclinical Testing Oncolytic Vaccinia Virus Strain GLV-5b451 Expressing an Anti-VEGF Single-Chain Antibody for Canine Cancer Therapy.

  Adelfinger M, Bessler S, Frentzen A, Cecil A, Langbein-Laugwitz J, Gentschev I, Szalay AA. Adelfinger M, et al. Viruses. 2015 Jul 20;7(7):4075-92. doi: 10.3390/v7072811. Viruses. 2015. PMID: 26205404 Free PMC article.

• What Went Wrong with VEGF-A in Peripheral Arterial Disease? A Systematic Review and Biological Insights on Future Therapeutics.

  Kastora SL, Eley J, Gannon M, Melvin R, Munro E, Makris SA. Kastora SL, et al. J Vasc Res. 2022;59(6):381-393. doi: 10.1159/000527079. Epub 2022 Nov 15. J Vasc Res. 2022. PMID: 36380643 Free PMC article. Review.

• A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras.

  Desroches-Castan A, Quélard D, Demeunynck M, Constant JF, Dong C, Keramidas M, Coll JL, Barette C, Lafanechère L, Feige JJ. Desroches-Castan A, et al. Oncotarget. 2015 Mar 10;6(7):5382-411. doi: 10.18632/oncotarget.2979. Oncotarget. 2015. PMID: 25742784 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal